Molbio Diagnostics Ltd

Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited' at Panaji, as a private company dated October 20, 2000. Thereafter, Company was converted from a private limited company to a public limited company, and the name of Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to Company by the RoC. Company is innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. The Company entered into a joint venture agreement in August, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited, which started operations in 2000. Bigtec Innovations Private Limited got merged with the Company in 2015. It has developed Truenat' platform in 2015, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour. The Company works five manufacturing facilities in India, of which two are in Goa, one in Bengaluru, Karnataka and one in Visakhapatnam, Andhra Pradesh. Company is mainly engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-ray equipment's, single / dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, etc. In addition to this, it offer products globally to public health programs, diagnostic laboratories, and private and public hospitals. In February 2023, Company acquired 65.47% of the equity share capital of Prognosys Medical Systems Pvt Ltd to venture into radiology equipment. Further, in October 2024, Company acquired a 19.68 % equity stake in OptraScan Inc., a USA based company, to diversify to digital pathology scanners. Company is planning to raise Rs 200 Cr fresh issue equity shares by way of initial public offer and by issuing 12,556,000 equity shares of Re 1 each through offer for sale.